Merck responds to Arcoxia approvable letter

Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the MEDAL program. The company is hoping Arcoxia can take the place of Vioxx.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions